ITGB2 and familial pancreatic carcinoma: Despite significant advances in oncology, the estimated 5 year survival rate remains below 5%, underscoring its extremely poor prognosis.103,104 The present data conclusively demonstrate that VNPs exhibit strong anticancer activity against both T3M-4 and CD18/HPAF pancreatic cancer cell lines with an IC50 of ∼4 μg mL−1.